Invest

AlphaRose Therapeutics, born from a father's love for his daughter, is pioneering personalized medicine at scale for children with genetic diseases.

Our innovative approach rapidly develops and commercializes treatments for patients who are typically ignored by large pharma.

With over $1 million in funding, our lead product Rosiphersen is advancing towards a clinical trial led by a passionate, experienced team.

We are currently offering a public investment through a Reg CF offering for a limited time.